Enliven Therapeutics
ELVN----
Enliven Therapeutics (ELVN)
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients w...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- --
- Volume
- --
- Turnover
- --
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- --
- Volume Ratio
- --
- Turnover Ratio
- --
Enliven Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 20, 2026Price forecast
$66.8926.32%
Forecast & RatingStrong buy
10analysts
- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- PUBT · Jul 21 at 04:23 PM
Enliven Therapeutics CMO Helen Louise Collins disposes of USD 262,213 in common shares
- Market Beat · Jul 21 at 07:48 AM
The Goldman Sachs Group Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price
- rttnews · Jul 17 at 04:18 AM
Biotech Stocks At 52-Week Highs- CDNA, IART, AGL, BVS, ELVN
- MSN · Jul 10 at 06:43 PM
HMI Capital pares its stake in AI company nCino
- PUBT · Jul 8 at 04:18 PM
Enliven Therapeutics director Lori Anne Kunkel disposes of USD 504,256 common shares
- PUBT · Jun 24 at 06:20 PM
OrbiMed Advisors reports Enliven Therapeutics common stock sale worth $38.02 million
